- The document is a transcript of the Q1 FY27 Earnings Conference Call held on Thursday, August 06, 2026 at 4:00 p.m. (IST), following the company's results announcement earlier that day.
- The purpose of the event was to discuss Q1 FY27 financial results and provide business updates, including strategic developments and future outlook.
- Management participants included:
- Mr. Satish Mehta, Managing Director & CEO
- Mr. Tajuddin Shaikh, Chief Financial Officer
- Mr. Samit Mehta, Whole-Time Director and COO
- Mr. Vikas Thapar, President, Corporate Development, Strategy & Finance
- Mr. Piyush Nahar, Executive Vice President, Corporate Development & Strategy
- Mr. Saurabh Paliwal, Head, Investor Relations
- The transcript was being uploaded to the company website (www.emcure.com) as per regulatory requirements under Regulation 30 of SEBI LODR Regulations, 2015.
- The call included standard safe harbor statements noting that forward-looking statements are based on current expectations and subject to various risks and uncertainties.
Financial Highlights & Business Updates
Financial Performance Q1 FY27:
- Revenue: ₹2,580 crore, up 22.8% YoY
- EBITDA: ₹508 crore, up 25.8% YoY
- EBITDA Margin: 19.7%, expansion of 50 bps
- PAT: ₹292 crore, up 36.2% YoY
- PAT Margin: Improved 110 bps
- Gross Margin: 58.4%
- R&D Investment: ₹90 crore (3.5% of revenue)
- Gross Debt: ₹1,291 crore (as of June 30, 2026)
- Cash & Equivalents: ₹189 crore
- Net Debt: ₹1,103 crore
Business Segment Performance:
- Domestic Business: ₹1,095 crore, up 10.2% YoY
- Growth driven by CNS, cardiology, and gynecology brands
- In-licensed products from Sanofi and Roche contributing
- Zuventus showing stability after previous challenges
- Consumer business (Emcure Wellness) gaining traction with Bitter Drops
- International Business: ₹1,485 crore, up 34.2% YoY
- Europe: ₹537 crore, up 32.8% (driven by liposomal amphotericin B)
- Canada: ₹427 crore, up 24.6% (new launches and market share gains)
- Rest of World: ₹522 crore, up 44.8% (strong ARV performance)
Strategic Developments:
- Chairman Mr. Berjis Desai stepping down due to appointment to National Commission for Minorities (full-time government role)
- Mr. Satish Mehta to assume role of Chairman in addition to MD & CEO after AGM
- Mr. Samit Mehta appointed as Chief Operating Officer and CEO of Gennova
- Acquisition of remaining 12.05% minority stake in Gennova, making it 100% subsidiary
- Received 15+ product approvals across developed and emerging markets
Recent Initiatives:
- ICMR licensed novel anti-HPV candidate for Cervical Intraepithelial Neoplasia to Emcure (July 2026)
- Signed royalty-free, non-exclusive voluntary licensing agreement with Merck Sharp & Dohme for generic version of experimental monthly oral HIV pill (alimatravir) across 129 low and lower-middle income countries
Guidance & Outlook:
- Confident in delivering low to mid-teen revenue growth in FY27
- Committed to 70-100 basis points of EBITDA margin expansion
- Expect to become net cash by end of FY28
- R&D spending expected to be 4-5% of revenue for full year FY27
- Domestic business expected to grow in line with industry from Q2 onwards and faster than industry in second half
Additional Notes Section
- The document represents the complete transcript of the earnings conference call edited for accuracy and readability.
- The transcript includes detailed Q&A session with analysts from Axis Capital, Jefferies, Motilal Oswal, Kotak Institutional Equities, Sanctum Wealth, and Bank of Baroda Capital Markets.
- Key discussion topics included: domestic growth trajectory, Zuventus restructuring progress, Poviztra (semaglutide) market reception, geographic mix impact on margins, constant currency growth, and debt management strategy.